A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia

BACKGROUND: There are no previous reports of paliperidone palmitate's (PP) long term tolerability or pharmacokinetics of the highest dose in patients with schizophrenia. This study evaluates safety and tolerability, as well as pharmacokinetics, of the highest marketed dose of PP (150 mg eq. [23...

Descripción completa

Detalles Bibliográficos
Autores principales: Coppola, Danielle, Liu, Yanning, Gopal, Srihari, Remmerie, Bart, Samtani, Mahesh N, Hough, David W, Nuamah, Isaac, Sulaiman, Ahmad, Pandina, Gahan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3384238/
https://www.ncbi.nlm.nih.gov/pubmed/22455454
http://dx.doi.org/10.1186/1471-244X-12-26

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3384238/
https://www.ncbi.nlm.nih.gov/pubmed/22455454
http://dx.doi.org/10.1186/1471-244X-12-26

Ejemplares similares